Slide 1: Aytu BioScience to Acquire Neos Therapeutics
Aytu BioScience (NASDAQ: AYTU) Announced 12/10/20: Aytu BioScience to Acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) a ytubio.com 1
Slide 2: AYTU's Assertive M&A Has Created Platform to Drive Growth and Support Acquisitions
AYTU’s Assertive M&A Has Created Platform to Drive Growth and Support Acquisitions 2 Unique opportunity to acquire assets as a consolidator in a market ripe for integration Entered Pediatric Specialty Pharmaceutical Market Diversified into Consumer Health with Purchase of ~$30M Portfolio Expansion o
Slide 3: Acquisition of Neos Therapeutics: Transaction Highlights & Strategic Rationale
AYTU Acquisition of Neos Therapeutics: Transaction Highlights & Strategic Rationale x Transaction creates highly diversified specialty pharmaceutical company with $100M of pro forma revenue ‒ Brand Marketing (10 products), Pediatric, Primary Care, and Consumer Healthcare products x Accelerates trans
Slide 4: AYTU-NEOS Merger Synergies Will Create Robust Value and Expected to Drive Profitability
AYTU - NEOS Merger Synergies Will Create Robust Value and Expected to Drive Profitability 4 Continued Opportunities for Synergies SG&A • Commercial efficiencies • Duplicative overhead • Support functions and technology systems Operations • Manufacturing optimization • Streamlined R&D Upwards of $15
Slide 5: Additional Information about the Proposed Merger Transaction and Where to Find It
Additional Information about the Proposed Merger Transaction and Where to Find It This communication relates to the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 9, 2020, by and among Neos Therapeutics, Inc. (“Neos”), Aytu Bioscience Inc.
Slide 6: No Offer or Solicitation; Cautionary Statement Regarding Forward-Looking Statements
No Offer or Solicitation This communication does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor a solici tat ion of any vote or approval with respect to the proposed merger transaction or otherwise. No offering of securities shall be made except by means
Slide 7: Contact Information
7 Contact Information: Josh Disbrow Chief Executive Officer josh.disbrow@aytubio.com Investor Relations: James Carbonara Hayden IR james@haydenir.com Transfer Agent: Direct Transfer info@issuerdirect.com 877 - 481 - 4014